Michael and Josh welcome back Dr Andrew Jensen to help explore part two of OftiM's Head and Neck Cancer exploration party. With localised treatments done and dusted, the metastatic space is a daunting heterogeneous disease group. Twenty years ago, head and neck treatment relied on tried and true chemotherapy, but the last fifteen years have shown great strides regarding treatment options and outcomes. The first leap forward was cetuximab added to a chemotherapy backbone, making it the weapon of choice for oncologists worldwide. But like all great civilisations, pembrolizumab now dominates, showing how it can be effective when combined with existing treatment options.

A star-studded episode and one not to be missed!

Links to studies discussed in this episode (subscription may be required):

1. NCT00122460- https://www.nejm.org/doi/full/10.1056/nejmoa0802656
2. Keynote 048- https://www.thelancet.com/article/S0140-6736(19)32591-7/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Hosted on Acast. See acast.com/privacy for more information.